Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study

BACKGROUND: Prostate cancer (PCa) accounts for 20% of all cancers in subjects over 50 years in Italy. The majority of patients with PCa present with localized disease at the time of diagnosis, but many patients develop recurrent metastatic disease after treatment with curative intent. Androgen depri...

Descripción completa

Detalles Bibliográficos
Autores principales: Restelli, Umberto, Ceresoli, Giovanni Luca, Croce, Davide, Evangelista, Laura, Maffioli, Lorenzo Stefano, Gianoncelli, Letizia, Bombardieri, Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724712/
https://www.ncbi.nlm.nih.gov/pubmed/29263702
http://dx.doi.org/10.2147/CMAR.S148323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724712/
https://www.ncbi.nlm.nih.gov/pubmed/29263702
http://dx.doi.org/10.2147/CMAR.S148323

Ejemplares similares